Background: Resistant hypertension (RH) affects about 15-20% of treated hypertensive
patients worldwide. RH increases the risk of cardiovascular events such as myocardial
infarction and stroke by 50%. The pathological mechanisms underlying resistance to treatment
are still poorly understood.
Objective: The main goal of this pilot study was to determine and compare plasma metabolomic
profiles in resistant and non-resistant hypertensive patients.
Methods: We applied untargeted metabolomic profiling in plasma samples collected from 69
subjects with RH and 81 subjects with controlled hypertension. To confirm patients’ compliance
to antihypertensive treatment, levels of selected drugs and their metabolites were determined
in plasma samples with the LC-ESI-TOF/MS technique.
Results: The results showed no statistically significant differences in the administration of
antihypertensive drug in the compared groups. We identified 19 up-regulated and 13 downregulated
metabolites in the RH.
Conclusion: The metabolites altered in RH are linked to oxidative stress and inflammation,
endothelium dysfunction, vasoconstriction and cell proliferation. Our results may generate
new hypothesis about RH development and progression.